$LUDG

Ludwig Enterprises is an early-stage genomic technology company developing screening tests for inflammation-related chronic diseases, including cancers. Its platform combines mRNA inflammatory biomarkers, machine-learning algorithms and at-home cheek-swab kits. Its first product candidate, the Revealia Breast test, is designed to analyze mRNA signatures associated with breast cancer and is intended as a screening aid, not a definitive diagnosis. Ludwig is also developing tests for lung, ovarian and pancreatic cancers. The company is headquartered in Miami, Florida, and its operations are limited to the United States. Ludwig expects to make money by commercializing laboratory-developed tests, initially through the Revealia Breast test. Its planned business-to-business-to-consumer model uses healthcare providers and other institutional partners to connect patients with testing, with samples analyzed by CLIA-certified, CAP-accredited laboratories. Revenue may come from per-test patient payments, licensing its algorithms to partner laboratories, or testing services performed by its affiliated laboratory.